Introduction {#s1}
============

Colorectal cancer (CRC) is one of the most frequent neoplasms and an important cause of mortality in the developed world. This cancer is caused by both genetic and environmental factors although 35% of the variation in CRC susceptibility involves inherited genetic differences. Mendelian syndromes account for about 5% of the total burden of CRC, being Lynch syndrome and familial adenomatous polyposis the most common forms. Lynch syndrome tumors develop mainly as a consequence of defective DNA mismatch repair (MMR) associated with germline mutations in the *MLH1*, *MSH2*, *MSH6* and *PMS2* genes [@pone.0095022-Jasperson1]. Once clinical criteria for this syndrome are complied, genetic screening of these genes is performed when a MMR defect is detected in the patient\'s tumor. When a pathogenic variant is detected, management of this disease can be significantly improved by identifying carriers that will benefit from specific screening, preventive, and therapeutic measures. Also, identifying non-carriers in additional family members permit to release these individuals from intensive surveillance. Noteworthy, a significant proportion of variants identified in the MMR genetic screening correspond to missense or noncoding changes without a clear pathogenic consequence, and they are designated as "variants of uncertain significance" (VUS). Therefore, differentiating pathogenic and neutral genetic variants is still a major challenge in clinical genetics [@pone.0095022-Rasmussen1].

The c.1852_1853delinsGC (p.K618A) variant in the *MLH1* gene corresponds to a clear example of VUS in Lynch syndrome. When consulting the Leiden Open Variation Database (LOVD v.2.0), there are 120 entries for this variant [@pone.0095022-Fokkema1]. Available past studies reached contradictory conclusions about its pathogenicity reporting harmful *in silico* predictions [@pone.0095022-Chao1], absence of splicing or mRNA alteration [@pone.0095022-Tournier1], presence in patients with a defective MMR tumor [@pone.0095022-Caldes1], co-occurrence with clearly pathogenic MMR mutations [@pone.0095022-Liu1], apparent segregation with disease [@pone.0095022-Pastrello1], and a majority of non-altered *in vitro* functional studies [@pone.0095022-Takahashi1], [@pone.0095022-Hinrichsen1]. All previous data permitted to categorize it in LOVD as a class 1 variant (non-pathogenic/low clinical significance) [@pone.0095022-InSiGHT1]. Therefore, it should be considered as a neutral variant in terms of its implication with Lynch syndrome.

Recently, genome-wide association studies (GWAS) successfully identified so far 30 common, low-penetrance susceptibility variants in 25 risk loci for CRC [@pone.0095022-Tenesa1]--[@pone.0095022-Peters1]. Some genetic variants in hereditary CRC genes labeled as VUS could constitute low-penetrance risk alleles for CRC. Indeed, this hypothesis has been previously tested for some variants in those genes [@pone.0095022-Picelli1]. In agreement with this rationale, the main aim of the present study was to assess the implication of the c.1852_1853delinsGC (p.K618A) variant in the *MLH1* gene as a low-penetrance risk variant for CRC by performing a case-control study within a large cohort from the COGENT consortium-COST Action BM1206, an international effort to facilitate the study of inherited genetic predisposition to CRC [@pone.0095022-Tomlinson2], [@pone.0095022-HoulstonRSmembersof1].

Materials and Methods {#s2}
=====================

Study population {#s2a}
----------------

The current genetic association study totalized 8,055 CRC cases and 10,668 controls from 7 different cohorts (Edinburgh, Epicolon, Groningen, Kiel, Leiden, Milano, Stockholm) and recruitment details are summarized below. The study was approved by the institutional ethical committee of each participating hospital and written informed consent was obtained from all patients.

### Edinburgh cohort (1,553 CRC cases and 932 controls) {#s2a1}

A population-based series of patients from throughout Scotland, who were diagnosed with colorectal cancer when they were less than 55 years of age, were recruited to the study between February 1999 and June 2004. During the same period, unaffected controls were ascertained from a population-based register (community health index) and were invited to participate.

### Epicolon (2,001 CRC cases and 1,647 controls) {#s2a2}

Cases and controls were recruited through the EPICOLON Consortium that is based on a prospective, multicenter and population-based epidemiology survey of the incidence and features of CRC in the Spanish population [@pone.0095022-Piol1]. Briefly, cases were selected as patients with *de novo* histologically confirmed diagnosis of colorectal adenocarcinoma. Exclusion criteria were hereditary CRC forms, such as Lynch syndrome and familial adenomatous polyposis (FAP) and a personal history of inflammatory bowel disease. Controls were from the Spanish National DNA bank and were confirmed not to have cancer or history of neoplasm and no family history of CRC. All cases and controls were of Caucasian ethnicity.

### Groningen (559 CRC cases and 501 controls) {#s2a3}

Unselected CRC cases and hospital patient controls from the Netherlands included in the SCOPE project.

### Kiel (1,768 CRC cases and 2.030 controls) {#s2a4}

Cases and controls from population-based biobank projects including POPGEN (Population Genetic Cohort) from Schleswig-Holstein, north Germany, and SHIP (Survey of Health in Pommerania) from east and north-east Germany.

### Leiden (505 CRC cases and 836 controls) {#s2a5}

Cases and controls were recruited as previously described [@pone.0095022-Middeldorp1]. Briefly, most of the cases were recruited through the clinical genetics department. All cases were diagnosed with CRC and had early onset and/or positive family history for CRC. Known dominant polyposis syndromes, HNPCC/Lynch syndrome or bi-allelic MutYH mutation carriers were excluded. A single proband from each family was included in this study. Controls were healthy blood donors from the southwest region of the Netherlands. All cases and controls were of Caucasian ethnicity.

### Milano (619 CRC cases and 2,526 controls) {#s2a6}

Briefly, the cases were consecutive individuals affected with CRC who underwent surgery at the Fondazione IRCCS Istituto Nazionale Tumori in Milan (INT). The controls were blood donors recruited through the Immunohematology and Transfusion Medicine Service of INT the Associazione Volontari Italiani Sangue Comunale in Milan. All cases and controls were of Caucasian ethnicity.

### Stockholm (1,729 CRC cases and 1,487 controls) {#s2a7}

Unselected cases ascertained through 12 hospitals serving the Stockholm-Gotland and Uppsala-Örebro health-care regions in Sweden and blood donor controls.

Genotyping {#s2b}
----------

DNA was obtained from peripheral blood by standard extraction procedures. Allelic discrimination to genotype the c.1852_1853delinsGC (p.K618A) variant in the *MLH1* gene was performed by using a custom assay with the TaqMan allelic discrimination system (Life Technologies, Foster City, USA). As quality control, DNA from a known carrier of this variant was used as positive control, as well as duplicates and negative controls for amplification. Data could be available upon request. An example of allelic discrimination for this variant is shown in [**Figure 1**](#pone-0095022-g001){ref-type="fig"}.

![Allelic discrimination for c.1852_1853delinsGC (p.K618A) variant in the *MLH1* gene by using the TaqMan system.\
Red dots correspond to non-carriers (AA/AA genotype) and green dots to heterozygous carriers (AA/GC).](pone.0095022.g001){#pone-0095022-g001}

Statistical analysis {#s2c}
--------------------

To test the association between the c.1852_1853delinsGC (p.K618A) variant in the *MLH1* gene and CRC risk, odds ratios (OR) and 95%CI were calculated for each genotype by using PLINK v1.07 [@pone.0095022-Purcell1], separately in each cohort and globally. No deviation of the genotype frequency in controls from those expected under Hardy-Weinberg equilibrium (HWE) was detected by χ^2^ test (1 df) (P-value = 0.6294) [@pone.0095022-Wigginton1].

In order to explore if personal and/or familial characteristics were associated with the presence of the c.1852_1853delinsGC (p.K618A) variant in the *MLH1* gene, univariate analysis was performed restricted to the CRC cases from the Epicolon cohort due to data availability in this cohort. The selected clinical variables to be evaluated were gender, age (dichotomized by 50 y.o.), location of CRC, previous neoplasm, previous/synchronous adenoma, CRC familiy history (any relative with CRC), Lynch syndrome family history (any relative affected), microsatellite instability (MSI) and TNM tumor stage. Categorical variables were compared by the χ^2^ test (1 df), applying the Yates\' correction when needed. All *P*-values were two-sided, and a value less than 0.05 was considered statistically significant. Calculations were performed using the SPSS software version 18.0 (SPSS Inc, Chicago, Ill).

Results and Discussion {#s3}
======================

Genotyping for the c.1852_1853delinsGC (p.K618A) variant in the *MLH1* gene was successful in 8,055 CRC cases and 10,668 controls from 7 independent cohorts. Percentage of carriers varied between 0.4--2.6% in CRC cases and 0.5--3.1% for controls in the different cohorts, being 1.4% and 1.5% in the entire cohort for CRC cases and controls, respectively. Genotypic association results are shown in [**Table 1**](#pone-0095022-t001){ref-type="table"} for each cohort and globally. No association of this variant with CRC risk was detected neither in a specific cohort nor globally.

10.1371/journal.pone.0095022.t001

###### Genotypic association results for the *MLH1* c.1852_1853delinsGC (p.K618A) variant in 18,723 individuals from 7 cohorts.

![](pone.0095022.t001){#pone-0095022-t001-1}

  Cohort           Controls     \%      Cases      \%     OR     lower   upper   *P*-value
  -------------- ------------ ------ ----------- ------ ------- ------- ------- -----------
  *Edinburgh*                                                                   
  AA/AA             1,539      99.1      916      98.3   1.000                     0.087
  AA/GC               14       0.9       16       1.7    1.904   0.934   3.884  
  Total             1,553                932                                    
  *Epicolon*                                                                    
  AA/AA             1,596      96.9     1,949     97.4   1.000                     0.368
  AA/GC               51       3.1       52       2.6    0.839   0.574   1.228  
  Total             1,647               2,001                                   
  *Groningen*                                                                   
  AA/AA              555       99.3      497      99.2   1.000                     1.000
  AA/GC               4        0.7        4       0.8    1.116   0.281   4.438  
  Total              559                 501                                    
  *Kiel*                                                                        
  AA/AA             2,003      98.7     1,752     99.1   1.000                     0.282
  AA/GC               27       1.3       16       0.9    0.680   0.368   1.259  
  Total             2,030               1,768                                   
  *Leiden*                                                                      
  AA/AA              832       99.5      503      99.6   1.000                     1.000
  AA/GC               4        0.5        2       0.4    0.828   0.152   4.503  
  Total              836                 505                                    
  *Milano*                                                                      
  AA/AA             2,526      98.8      614      99.2   1.000                     0.525
  AA/GC               30       1.2        5       0.8    0.688   0.268   1.767  
  Total             2,556                619                                    
  *Stockholm*                                                                   
  AA/AA             1,466      98.6     1,700     98.3   1.000                     0.571
  AA/GC               21       1.4       29       1.7    1.188   0.680   2.074  
  Total             1,487               1,729                                   
  ***GLOBAL***                                                                  
  AA/AA             10,517     98.6     7,931     98.5   1.000                     0.501
  AA/GC              151       1.4       124      1.5    1.088   0.859   1.377  
  ** Total**      **10,668**          **8,055**                                 

OR, odds ratio.

In order to further explore the putative implication of this *MLH1* variant with CRC risk, we performed a case-only genotype-phenotype correlation restricted to the Epicolon cohort (2,001 CRC cases) with several clinical and pathological characteristics. Results are shown in [**Table 2**](#pone-0095022-t002){ref-type="table"}. Again, none of the analyzed variables showed a distinct association with the presence of the c.1852_1853delinsGC (p.K618A) variant. Results for CRC family history and Lynch syndrome family history were statistically significant but the presence of any of these variables was linked with the wild-type genotype (AA/AA). The rest of variables showed a similar distribution between carriers and non-carriers.

10.1371/journal.pone.0095022.t002

###### Genotype-phenotype correlation of the *MLH1* c.1852_1853delinsGC (p.K618A) variant with clinical and pathological characteristics in colorectal cancer cases from the Epicolon cohort.

![](pone.0095022.t002){#pone-0095022-t002-2}

                           CRC≤50    \%    CRC\>50    \%     OR     lower   upper   *P*-value
  ----------------------- -------- ------ --------- ------ ------- ------- ------- -----------
  **Age**                                                                          
  AA/AA                      97      5      1,841     95    1.000                     1.000
  AA/GC                      2      3.8      50      96.2   1.317   0.316   5.493  
  Total                      99             1,891                                  
                           Female    \%     Male      \%     OR     lower   upper   *P*-value
  **Gender**                                                                       
  AA/AA                     766     39.5    1,172    60.5   1.000                     0.388
  AA/GC                      17     32.7     35      67.3   1.346   0.749   2.419  
  Total                     783             1,207                                  
                           Colon     \%    Rectum     \%     OR     lower   upper   *P*-value
  **CRC location**                                                                 
  AA/AA                    1,267    65.9     656     34.1   1.000                     0.882
  AA/GC                      33     64.7     18      35.3   1.053   0.589   1.885  
  Total                    1,300             674                                   
                             No      \%      Yes      \%     OR     lower   upper   *P*-value
  **Previous neoplasm**                                                            
  AA/AA                    1,290    73.8     458     26.2   1.000                     0.624
  AA/GC                      39      78      11       22    0.794   0.403   1.564  
  Total                    1,329             469                                   
                             No      \%      Yes      \%     OR     lower   upper   *P*-value
  **Prev/sync adenoma**                                                            
  AA/AA                    1,268    71.2     513     28.8   1.000                     0.112
  AA/GC                      41      82       9       18    0.543   0.262   1.124  
  Total                    1,309             522                                   
                             No      \%      Yes      \%     OR     lower   upper   *P*-value
  **CRC FH**                                                                       
  AA/AA                    1,652    85.2     286     14.8   1.000                     0.026
  AA/GC                      50     96.2      2      3.8    0.231   0.056   0.955  
  Total                    1,702             288                                   
                             No      \%      Yes      \%     OR     lower   upper   *P*-value
  **Lynch FH**                                                                     
  AA/AA                    1,401    81.5     317     18.5   1.000                     0.048
  AA/GC                      42     93.3      3      6.7    0.316   0.097   1.025  
  Total                    1,443             320                                   
                             No      \%      Yes      \%     OR     lower   upper   *P*-value
  **MSI**                                                                          
  AA/AA                    1,308     94      84       6     1.000                     0.731
  AA/GC                      37     92.5      3      7.5    1.263   0.381   4.180  
  Total                    1,345             87                                    
                           I--II     \%    III--IV    \%     OR     lower   upper   *P*-value
  **TNM**                                                                          
  AA/AA                     909     53.7     783     46.3   1.000                     1.000
  AA/GC                      26     53.1     23      46.9   1.027   0.581   1.814  
  Total                     935              806                                   

CRC, colorectal cancer; OR, odds ratio; Prev/Sync, Previous/Synchronous; FH, family history; MSI, microsatellite instability; TNM, tumor-node-metastasis.

Obviously, genetic variants causing a missense mutation have a less clear pathogenic interpretation than those causing a premature termination of the protein. The c.1852_1853delinsGC (p.K618A) variant in the *MLH1* gene is a prominent example of a VUS that has been controversial for many years in the context of Lynch syndrome genetic diagnosis. However, recent functional studies have permitted to characterize more thoroughly its real effect of the MLH1 protein and it can be concluded that its effect is neutral or with very subtle effect [@pone.0095022-Tournier1], [@pone.0095022-Pastrello1]--[@pone.0095022-InSiGHT1].

Regarding its putative implication in CRC risk as a rare low-penetrance variant, previous studies were sparse and included a small number of CRC cases and controls [@pone.0095022-Christensen1], [@pone.0095022-Castillejo1]. Consequently, it was justified to perform a case-control association study in a large cohort in order to reach more solid conclusions. Our results showed no involvement of this variant in CRC risk as a low-penetrance variant in the *MLH1* gene.

Regarding its putative implication in familial CRC, this variant was also seen to be over-represented in families with suspected Lynch syndrome in a previous study [@pone.0095022-Medeiros1]. Our results will be not in agreement with this previous observation since the K618A variant was not linked in the Epicolon cohort to the presence of CRC family history and Lynch syndrome family history. Therefore, our study is adding to the existing literature by showing that this variant is not linked to familial CRC.

Finally, we can conclude from our results and previous evidence that the c.1852_1853delinsGC (p.K618A) variant in the *MLH1* gene should be regarded from now on as a polymorphism without functional effect on the MLH1 protein, no role in genetic predisposition to Lynch syndrome, as well as no apparent effect as a low-penetrance variant for CRC genetic susceptibility.
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